Review article:: rabeprazole-based therapy in Helicobacter pylori eradication

被引：19

作者：

Barth, J ^{[1
]}

Hahne, W ^{[1
]}

机构：

[1] Eisai Inc, Clin Res & Dev, Teaneck, NJ 07666 USA

来源：

ALIMENTARY PHARMACOLOGY & THERAPEUTICS | 2002年 / 16卷

关键词：

D O I：

10.1046/j.1365-2036.2002.0160s1031.x

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Rabeprazole's favourable pharmacodynamic profile is a result of its rapid onset and its 24-h control of gastric parietal secretion. These qualities, and its antimicrobial properties, make it particularly effective in the treatment of Helicobacter pylori (H. pylori), which is a short course of treatment compared to other conditions treated with proton pump inhibitors. Recently completed trials in combination with amoxicillin, clarithromycin and metronidazole for 7 days achieved high eradication of H. pylori. An additional study assessing the efficacy of combined rabeprazole and antibiotic treatments of 3, 7. and 10 days' duration vs. FDA-approved 10-day omeprazole triple therapy is under way to address the possibility of shorter duration therapies in the USA.

引用

页码：31 / 33

页数：3

共 10 条

[1] Sites of reaction of the gastric H,K-ATPase with extracytoplasmic thiol reagents [J].